Highlights
- Vulvovaginal melanoma is a rare disease, with minimal available data on molecular and immunologic characteristics.
- Vulvovaginal melanoma has less frequent BRAF and more frequent KIT, ATRX, and SF3B1 mutations than cutaneous melanoma.
- High tumor mutation burden was absent in vulvovaginal melanoma tumors, compared with 50% TMB-H cutaneous melanomas.
- Vulvovaginal melanoma patients receiving immune checkpoint inhibitor therapy had a shorter OS compared to cutaneous patients.